---
title: "Sionna Therapeutics set to open 50% above offer price after upsized $191 mln IPO"
date: "2025-02-08 00:39:52"
summary: "** Shares of drug developer Sionna Therapeutics (SION.O) set to open 50% above their offer price in their Nasdaq debut** Stock indicated to open at $27 vs $18 IPO price** SION sold ~10.6 mln shares, 20% more than initially offered, at the top end of its marketed range of $16..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

\*\* Shares of drug developer Sionna Therapeutics (SION.O) set to open 50% above their offer price in their Nasdaq debut

\*\* Stock indicated to open at $27 vs $18 IPO price

\*\* SION sold ~10.6 mln shares, 20% more than initially offered, at the top end of its marketed range of $16 to $18 apiece to raise $190.6 mln

\*\* At the IPO price, the Waltham, Massachusetts-based firm fetched a valuation of $765.4 mln

\*\* Founded in 2019 and previously known as Sling Therapeutics, SION is developing drugs to treat cystic fibrosis

\*\* SION is vying for a slice of the cystic fibrosis market that is dominated by drugmaker Vertex Pharmaceuticals

\*\* Vertex booked almost $10 billion in sales in 2023 and has significantly impacted cystic fibrosis treatment

\*\* SION is evaluating its experimental drug candidates SION-719 and SION-451 in early-stage trials in Australia

\*\* Prior to the IPO, SION had raised about $330 mln from investors, including RA Capital, TPG's Rise Fund, and Atlas Venture

\*\* Goldman Sachs, TD Cowen, Stifel and Guggenheim Securities were the underwriters

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3OY1J7:0-sionna-therapeutics-set-to-open-50-above-offer-price-after-upsized-191-mln-ipo/)
